Presentation: Omalizumab Improves Asthma but Not Nasal Symptoms in Japanese Patients with Severe Allergic Asthma and Rhinitis (World Allergy Congress)

Wednesday, 7 December 2011: 14:00 - 14:15

Costa Maya 1 (Cancún Center)

Fuyumi Nishihara, MD , Allergy Center , Department of Respiratory Medicine, Saitama Medical University, Moroyama-Machi, Japan

Yotaro Takaku, MD, PhD , Allergy Center , Department of Respiratory Medicine, Saitama Medical University, Moroyama-Machi, Japan

Kazuyuki Nakagome, MD, PhD , Allergy Center , Department of Respiratory Medicine, Saitama Medical University, Moroyama-Machi, Japan

Takehito Kobayashi, MD, PhD , Allergy Center , Department of Respiratory Medicine, Saitama Medical University, Moroyama-Machi, Japan

Makoto Nagata, MD, PhD, Prof , Allergy Center , Department of Respiratory Medicine, Saitama Medical University, Moroyama-Machi, Japan

Background: There is evidence that humanized monoclonal antibody against IgE (Omalizumab) is effective in severe allergic asthma. In this study, we examined the effectiveness of omalizumab on asthma and nasal symptoms in Japanese patients with severe allergic asthma and rhinitis.

Methods: An open-label study that enrolled seven patients with both severe allergic asthma and rhinitis who visited Allergy Center, Saitama Medical University was performed. All patients presented uncontrolled asthma despite medication including high-dose inhalational corticosteroids, long-acting beta2-agonist, leukotriene receptor antagonist, theophylline, and oral predonisolone. Omalizumab was added on their treatments and symptoms score using Asthma Contol Test(ACT), peak expiratory flow rate(PEFR), exhaled nitric oxide (eNO), sputum eosinophils and nasal symptoms were evaluated before and 12-16 weeks after omalizumab.

Results: Omalizumab significantly improved ACT scores especially dose of rescue use of short-acting beta2-agonist (p<0.05) and PEFR (p<0.05). Furthermore, omalizumab significantly decreased exhaled both eNO (p<0.05) and the percentage of eosinophils in induced sputum. On the other hand, nasal symptoms were not change following induction of omalizumab.

Conclusions: Clinical effectiveness of omalizumab was confirmed in Japanese population of severe allergic asthma, but not rhinitis. The therapeutic potency of omalizumab on asthma likely involves anti-inflammatory properties such as decreasing eNO or airway eosinophilia.

4214 Omalizumab Improves Asthma but Not Nasal Symptoms in Japanese Patients with Severe Allergic Asthma and Rhinitis